Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell

doi:10.1128/JCM.00865-06

Back

Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

Journal article

Open access

Peer reviewed

Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

M A Pfaller, D J Diekema, M Mendez, C Kibbler, P Erzsebet, S-C Chang, D L Gibbs and V A Newell

Journal of clinical microbiology, Vol.44(10), pp.3551-3556

10/2006

DOI: 10.1128/JCM.00865-06

PMCID: PMC1594787

PMID: 17021081

Files and links (1)

url

https://doi.org/10.1128/JCM.00865-06View

Published (Version of record) Open Access

Abstract

Although a rare cause of invasive candidiasis, Candida guilliermondii has been reported to exhibit decreased susceptibility to antifungal agents. Aside from case reports and small surveys, there is little information regarding the epidemiology and antifungal susceptibility profile of C. guilliermondii. We report geographic and temporal trends in the isolation and antifungal susceptibilities of 1,029 C. guilliermondii clinical isolates collected from 127 medical centers as part of the ARTEMIS DISK Antifungal Surveillance Program. In addition, we report the in vitro susceptibility of 132 bloodstream isolates of C. guilliermondii to caspofungin. C. guilliermondii represented 1.4% of the 75,761 isolates collected from 2001 to 2003 and was most common among isolates from Latin America (3.7% versus 0.6 to 1.1%). Decreased susceptibility to fluconazole was noted (75% susceptible; range, 68 to 77% across regions), and voriconazole was more active in vitro against C. guilliermondii than fluconazole (91% susceptible; range, 88 to 93% across regions). Fluconazole was least active against isolates from dermatology (58%) and surgical (69%) services and against isolates associated with skin and soft tissue infection (68%, compared to 85% susceptible for bloodstream isolates). There was no evidence of increasing azole resistance over time among C. guilliermondii isolates tested from 2001 to 2003. Of 132 bloodstream isolates of C. guilliermondii tested against caspofungin, most were inhibited by < or =2 microg/ml (96%; MIC50/MIC90, 0.5/1.0 microg/ml). C. guilliermondii, a species that exhibits reduced susceptibility to fluconazole, is the sixth most frequently isolated Candida species from this large survey and may be an emerging pathogen in Latin America.

Global Health

Fluconazole - pharmacology

Humans

Candidiasis - epidemiology

Peptides, Cyclic - pharmacology

Pyrimidines - pharmacology

Candidiasis - microbiology

Triazoles - pharmacology

Candida - classification

Candidiasis - drug therapy

Voriconazole

Echinocandins

Candida - drug effects

Drug Resistance, Fungal

Lipopeptides

Population Surveillance

Details

Title: Subtitle: Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
Creators: M A Pfaller - Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
D J Diekema
M Mendez
C Kibbler
P Erzsebet
S-C Chang
D L Gibbs
V A Newell
Contributors: Global Antifungal Surveillance Group (Author)
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.44(10), pp.3551-3556
DOI: 10.1128/JCM.00865-06
PMID: 17021081
PMCID: PMC1594787
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 10/2006
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986371502771

Metrics

34 Record Views

146 Times Cited - Web of Science